KLK3 and neoplasm: Ipilimumab showed promising results of a significant decline in prostate-specific antigen (PSA) levels when given in combination with granulocyte macrophage colony-stimulating factor (GM-CSF) and anti-tumor activity in phase I and phase I/II clinical trials, respectively, in metastatic castration-resistant PCa (mCRPC).